Published in final edited form as:

Medchemcomm. 2015 February ; 6(2): 339–346. doi:10.1039/C4MD00441H.

EVALUATION OF AROMATIC 6-SUBSTITUTED THIENOPYRIMIDINES AS SCAFFOLDS AGAINST PARASITES THAT CAUSE TRYPANOSOMIASIS, LEISHMANIASIS, AND MALARIA

Jennifer L. Woodring^a, Gautam Patel^a, Jessey Erath^b, Ranjan Behera^c, Patricia J. Lee^d, Susan E. Leed^d, Ana Rodriguez^{b,e}, Richard J. Sciotti^d, Kojo Mensa-Wilmot^c, and Michael P. Pollastri^{*,a}

^aNortheastern University Department of Chemistry & Chemical Biology, 360 Huntington Avenue, Boston, MA 02115 USA. Tel: 617-373-2703

^bNew York University School of Medicine, Department of Microbiology, Division of Parasitology, 341 E. 25th St. New York, NY 10010 USA

^c University of Georgia, Department of Cellular Biology, Athens, GA 30602 USA

^d Experimental Therapeutics, Walter Reed Army Institute for Research, 2460 Linden Lane, Silver Spring, MD 20910 USA

^e Anti-Infectives Screening Core, New York University School of Medicine, New York, NY 10010 USA

Abstract

Target repurposing is a proven method for finding new lead compounds that target *Trypanosoma brucei*, the causative agent of human African trypanosomiasis. Due to the recent discovery of a lapatinib-derived analog **2** with excellent potency against *T. brucei* (EC₅₀ = 42 nM) and selectivity over human host cells, we have explored other classes of human tyrosine kinase inhibitor scaffolds in order to expand the range of chemotypes for pursuit. Following library expansion, we found compound **11e** to have an EC₅₀ of 84 nM against *T. brucei* cells while maintaining selectivity over human hepatocytes. In addition, the library was tested against causative agents of Chagas' disease, leishmaniasis, and malaria. Two analogs with sub-micromolar potencies for *T. cruzi* (**4j**) and *Plasmodium falciparum* (**11j**) were discovered, along with an analog with considerable potency against *Leishmania major* amastigotes (**4e**). Besides identifying new and potent protozoan growth inhibitors, these data highlight the value of concurrent screening of a chemical library against different protozoan parasites.

m.pollastri@neu.edu.

[†]Electronic Supplementary Information (ESI) available (See DOI: 10.1039/b000000x/): Synthetic preparations, assay details, *in vitro* ADME data, and additional malaria screening data are described in the ESI. The data tables are recapitulated with NEU registry numbers to enable searching within the public data set available at <http://collaborativedrug.com>.

Introduction

Human African trypanosomiasis (HAT) is a life-threatening parasitic disease that places 70 million people at risk in parts of Sub-Saharan Africa. Caused by the protozoan parasite *Trypanosoma brucei*, it is one of 17 neglected tropical diseases (NTDs) highlighted by the World Health Organization as needing new therapies. Current medicines for HAT are not orally bioavailable, have unfavorable toxicity profiles and drug resistant parasites are emerging.¹

Phosphodiesterase and kinase target repurposing² are rapid and pragmatic methods of lead drug discovery explored in our laboratory.³⁻⁸ Launching new antiparasitic drug discovery efforts by redirecting inhibitors of human drug targets that are homologous to essential parasite targets or pathways can facilitate rapid development of structure-activity relationships (SAR), and accelerate “hit” optimization.

Inhibition of human receptor tyrosine kinases (RTKs) is a widely employed approach for cancer therapeutics.⁹⁻¹² Specifically, an epidermal growth factor receptor (EGFR) inhibitor lapatinib (GW572016, Tykerb, **1**, **Figure 1**) was approved by the FDA in 2007 for solid tumors and breast cancer.¹³⁻¹⁶ Compound **1** proved to be a promising lead for HAT due to its modest potency against *T. brucei* with an EC₅₀ of 1.54 μ M, and its ability to cure 25% of infected mice in a murine model of HAT.¹⁷ Beginning with lapatinib, extensive SAR studies led to compound **2**, which has an EC₅₀ of 42 nM and excellent selectivity over human cells. Importantly, compound **2** was orally bioavailable in mice and had a modest effect on parasitemia and life extension in a murine *T. brucei* bloodstream infection despite exhibiting high plasma protein binding (>99%) and a lack of central nervous system exposure.⁷ These observed pharmacokinetic properties are not surprising due to its high LogP and molecular weight.

The previous SAR explorations of the lapatinib chemotype focused on the “head” and “tail” regions of the molecule, described in **Figure 1**. Historical tyrosine kinase inhibitor lead discovery efforts have led to many quinazoline scaffold replacements in cancer chemotherapy discovery.¹⁸⁻²¹ GW837016X (**3**) possesses a related core scaffold and was also found to be potent against *T. brucei*. It therefore seemed appropriate to utilize the thieno[3,2-*d*]pyrimidine (and the regioisomeric thieno[2,3-*d*]pyrimidine) scaffolds to launch a crossover SAR study, preparing analogs matched to those quinazoline-based inhibitors previously described⁷ (denoted in this article as **4b-m**, **Table 1**).

We recently demonstrated the value of simultaneously testing compounds against related protozoan parasites, wherein it became evident that producing parasite-dependent SAR could direct future work against each pathogen.⁸ In addition to the screening of new compounds against *T. brucei*, compounds were screened against the kinetoplastid parasites *Leishmania major* (causative agent of cutaneous leishmaniasis) and *T. cruzi* (which causes Chagas disease), as well as the malaria-causing parasite *Plasmodium falciparum*. In this report we disclose the results of our efforts to prepare and test thienopyrimidine-based inhibitors, matching the “tail” replacements explored in the previous study that led to compound **2**.⁷

Synthetic procedure

The requisite dihalo template precursors (**9** and **16**, **Schemes 1** and **2**) of the thieno[3,2-*d*]pyrimidine and thieno[2,3-*d*]pyrimidine scaffolds were made following previously disclosed protocols.²²⁻²⁵ The thieno[3,2-*d*]pyrimidine intermediate **9** was synthesized starting from methyl 3-aminothiophene-2-carboxylate (**5**) as shown in **Scheme 1**. This commercially available material underwent formylation, followed by cyclization with formamide and ammonium formate to afford intermediate **7**. The pyrimidinone **7** was chlorinated using phosphorous oxychloride to provide **8** and brominated using 1,2-dibromo-1,1,2,2-tetrafluoroethane to yield the key thienopyrimidine **9**. From this point, halide displacement with the requisite aniline in refluxing isopropanol produced the bromide intermediate **10**, amenable for subsequent Suzuki chemistry.

Reagents and conditions: (a) HCO₂H, Ac₂O, 0 °C to RT, 12 h, 79%; (b) HCONH₂, NH₄HCO₂, 150 °C to RT, 17 h, 56%; (c) POCl₃, 110 °C, 12 h, 90%; (d) LDA, C₂Br₂F₄, THF, -78 °C to RT, 13 h, 94%; (e) 3-chloro-4-((3-fluorobenzyl)oxy)aniline, IPA, 85 °C, 12 h, 88%; (f) Boronic ester, Na₂CO₃, Pd(PPh₃)₄, DME/EtOH (3:2), H₂O, 80-85 °C, 12 h, 8-36%

The thieno[2,3-*d*]pyrimidine template was synthesized from commercially available methyl 2-cyanoacetate (**12**, **Scheme 2**), which underwent Gewald reaction conditions with 1,4-dithiane-2,5-diol to produce the desired aminothiophene **13**. Cyclization of the thiophene with formamide afforded intermediate **14**, followed by sequential bromination (**15**), and chlorination to provide **16**. As before, aniline displacement of the chloride was effected smoothly, providing **17** for further diversification via Suzuki reaction. For both scaffolds, intermediate **10** or intermediate **17** was coupled with boronic esters or acids using Suzuki reaction conditions to generate the respective final compounds **11a-m** and **18a-j**, which are matched with corresponding quinazoline analogs previously reported (**Table 1**).⁷

Reagents and conditions: (a) 1,4-dithiane-2,5-diol, TEA, DMF, 45 °C, 2 h, 58%; (b) HCONH₂, 170 °C, 6 h, 38%; (c) Br₂, AcOH, 80 °C, 2 h, 79%; (d) POCl₃, 100 °C, 12 h, 75%; (e) 3-chloro-4-((3-fluorobenzyl)oxy)aniline, IPA, 85 °C, 12 h, 88%; (f) Boronic ester, Na₂CO₃, Pd(PPh₃)₄, DME/EtOH (3:2), H₂O, 85 °C, 12 h, 20-46%

Results and discussion

Tests of the compounds against *T. brucei* revealed favorable growth inhibitory activity amongst three distinct scaffolds shown in **Table 1**. To make the direct comparison with **2**, replacement of the quinazoline with thieno[2,3-*d*]pyrimidine (**18a**) yielded a 10x change in potency, whereas the thieno[3,2-*d*]pyrimidine replacement (**11a**) resulted in a dramatic loss of potency. Removal of the morpholine altogether (**4b**, **11b**, **18b**) or the tail altogether (**4m**, **11m**) reduced the potency to the micromolar range.

An additional atom linker between the phenyl and morpholine was more favored on the quinazoline scaffold (**4j**) than the thienopyrimidines (**11j** and **18j**) but still showed reduced potency. Evaluation of the morpholine regiochemistry revealed that *para* (**4k**, **11k**) was less potent than *meta* (**2**, **11a**, **18a**), though alteration of this regiochemistry was better tolerated

when attached to the thieno[3,2-*d*]pyrimidine **11k** than the quinazoline scaffold **4k**. The most potent compound from this series is **11e**, an 84 nM inhibitor of *T. brucei* cell growth. This “tail” was not as potent in the quinazoline scaffold (**4e**); the morpholinophenyl tail present in **2** remains the most potent analog overall with an EC₅₀ of 42 nM. For the most potent analogs in the thieno[2,3-*d*]pyrimidine scaffold, both the 5-methyl-6-morpholinopyridin-3-yl tail (**18e**) and the morpholinophenyl tail (**18a**) were equipotent with EC₅₀ values of 420 and 400 nM respectively, but the 3-phenyl(piperidin-1-yl)methanone analog (**18h**) was slightly more potent with an EC₅₀ of 330 nM.

Figure 2 displays the effect of changing the scaffold, while maintaining the R-group substitution, upon anti-*T. brucei* activity. We can make a few observations from this qualitative analysis. First, in the majority of cases, switching from quinazoline (black circles) to thieno[2,3-*d*]pyrimidine (red circles) tends to improve compound potency (*i.e.*, reduces EC₅₀ 3-fold or more). Second, when comparing matched analogs between the quinazoline and thieno[3,2-*d*]pyrimidine scaffolds, except for **18c** versus **4c**, which is about a 9-fold difference; 0.5 versus 4.7 μM, the difference in activity is seldom greater than two-fold. This indicates that thieno[3,2-*d*]pyrimidines, unlike thieno[2,3-*d*]pyrimidines, are equipotent to quinazolines when tested against *T. brucei*. Third, the range of activities for compounds with thienopyrimidine scaffolds is narrower (0.084 - 2.9 μM) than the quinazolines (0.042 – 6.5 μM). Fourth, for matched pairs of the [3,2-*d*] and [2,3-*d*] scaffold, there is seldom more than a 2-fold difference in EC₅₀ (the only exception being **11j** (EC₅₀= 1.1 μM) vs **18j**, which only inhibits parasite growth 60% at 5 μM).

Table 1 also shows the results of testing these analogs against the other protozoan parasites. Compound **2** and its related thienopyrimidine-derived analogs **11a** and **18a** had shown sub-micromolar potency towards the malaria parasite *P. falciparum*. Removal of the “tail” (**4m**, **11m**) or of the morpholine (**4b**, **11b**, **18b**) produced a significant loss in potency across all 3 scaffolds. Any *ortho* substitution on the phenyl portion of the tail was not well tolerated by any set. The three tails that produced the most potent analogs were the meta substituted methylsulfonyl (**4d**, **11d**, **18d**), the para substituted methyl-pyridinylmorpholine (**4e**, **11e**, **18e**), and the para substituted benzylmorpholine (**4j**, **11j**, **18j**). These tails consistently showed sub-micromolar EC₅₀ values across all three scaffolds, suggesting that appropriately placed H-bond acceptors may be crucial to antimalarial activity in this region. These compounds were also tested against two drug resistant strains of malaria (W2, C235) and were generally found to show potencies within 3-fold of the D6 strain (Table S2, Figure S1 Electronic Supplemental Information (ESI)).

Although **2** and the corresponding thieno[2,3-*d*]pyrimidine analog **18a** displayed promising micromolar potency against *T. cruzi*, overall the thieno[3,2-*d*]pyrimidine analogs were more potent in this study, with the best compounds being **4j** (EC₅₀ = 0.60 μM), **11c** (0.67 μM), and **11i** (0.75 μM). Quinazolines tolerated the removal of the morpholino group better than either of the thienopyrimidines. Though the *para*-morpholinophenyl tail (**4k**, **11k**) was inactive in this assay, adding an intervening methylene group (**4j** and **11i**) resulted in active analogs.

Screening of more than 35 compounds against amastigotes of *Leishmania major* failed to produce any sub-micromolar compounds. The most potent analog across all 3 scaffolds against *Leishmania major* amastigotes was **4e** with an EC₅₀ of 1.14 μM. Against promastigotes of *L. major* only **11j** had sub-micromolar potency (EC₅₀ = 220 nM). As seen with other drug sensitivity studies, there is often little-to-no correlation between the effect of compounds on intracellular amastigotes and the promastigote form of *Leishmania*.²⁶

Most compounds showed no toxicity to the HepG2 cell line except **4b**, **4j**, **4k**, and **18b** with TC₅₀ values (concentration leading to 50% growth inhibition of host cells) of 4.9, 12.9, 9.6, and 10.0 μM respectively.

We tested the two most potent *T. brucei* growth inhibitors **2** and **11e** in *in vitro* ADME assays, and observed that, as predicted based on their high cLogP (7.6 and 7.4 respectively), both have poor solubility (< 1 μM), high protein binding (>99%), and modest metabolic stability (**Table S3**, **ESI**). Nonetheless, as the goal of this report was to describe SAR between the quinazoline and thienopyrimidine scaffolds, we are encouraged by the reasonable SAR tracking that is observed between the different scaffolds. Work continues on all three scaffolds to improve their physicochemical properties, primarily focused upon reducing size and lipophilicity: Results will be reported in due course.

Conclusions

We have previously shown that some lapatinib-derived analogs have high potency towards the HAT parasite *T. brucei* and with little host cell toxicity, typified by **2** (EC₅₀ = 42 nM). In assessing matched [3,2-d] and [2,3-d] thienopyrimidine scaffold replacements, we have discovered analogs, such as **11e**, that have excellent potency against *T. brucei* cells (EC₅₀ = 84 nM). Also, a multi-pathogen testing campaign using these *T. brucei* inhibitors against select protozoan parasites produced compounds with a variety of favorable potencies: **4j**, *T. cruzi* EC₅₀ = 0.60 μM; **4e**, *L. major* amastigote EC₅₀ = 1.14 μM and **11j**, *P. falciparum* EC₅₀ = 0.027 μM. While these data are indicative of good starting points for antiparasite drug discovery, attention must be paid to improvement of the physicochemical properties of these agents in order to produce effective drugs.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

This work was funded in part by NIH grants R01AI082577 (MPP), R56AI099476 (MPP and KM-W), and R21AI076647 (KM-W). We thank GlaxoSmithKline for providing GW837016X that was used in exploratory studies with *T. brucei*. We appreciate a free academic license for the OpenEye suite of software, and are grateful to AstraZeneca for performing the *in vitro* ADME experiments described in this manuscript.

References

1. World Health Organization Fact Sheet No. 259. <http://www.who.int/mediacentre/factsheets/fs259/en/>, Accessed 28 July 2014
2. Pollastri MP, Campbell RK. Future Med. Chem. 2011; 3:1307–1315. [PubMed: 21859304]

3. Bland ND, Wang C, Tallman C, Gustafson AE, Wang Z, Ashton TD, Ochiana SO, McAllister G, Cotter K, Fang AP, Gechijian L, Garceau N, Gangurde R, Ortenberg R, Ondrechen MJ, Campbell RK, Pollastri MP. *J. Med. Chem.* 2011; 54:8188–8194. [PubMed: 22023548]
4. Diaz-Gonzalez R, Kuhlmann FM, Galan-Rodriguez C, Silva L. M. d. Saldivia M, Karver CE, Beverley SM, Rodriguez A, Navarro M, Pollastri MP. *PLoS Negl. Trop. Dis.* 2011; 5:e1297. [PubMed: 21886855]
5. Seixas JD, Luengo-Arratta SA, Diaz R, Saldivia M, Rojas-Barros DI, Manzano P, Gonzalez S, Berlanga M, Smith TK, Navarro M, Pollastri MP. *J. Med. Chem.* 2014; 57:4834–4848. [PubMed: 24805946]
6. Ochiana SO, Pandarinath V, Wang Z, Kapoor R, Ondrechen MJ, Ruben L, Pollastri MP. *Eur. J. Med. Chem.* 2013; 62:777–784. [PubMed: 22889561]
7. Patel G, Karver CE, Behera R, Guyett PJ, Sullenberger C, Edwards P, Roncal NE, Mensa-Wilmot K, Pollastri MP. *J. Med. Chem.* 2013; 56:3820–3832. [PubMed: 23597080]
8. Patel G, Roncal NE, Lee PJ, Leed SE, Erath J, Rodriguez A, Sciotti RJ, Pollastri MP. *MedChemComm.* 2014; 5:655–658. [PubMed: 24910766]
9. Cockerill GS, Lackey KE. *Curr. Top. Med. Chem.* 2002; 2:1001–1010. [PubMed: 12171567]
10. Traxler P. *Expert Opin. Ther. Targets.* 2003; 7:215–234. [PubMed: 12667099]
11. Baselga J, Arteaga CL. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology.* 2005; 23:2445–2459. [PubMed: 15753456]
12. Hynes NE, Lane HA. *Nat. Rev. Cancer.* 2005; 5:341–354. [PubMed: 15864276]
13. Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, Keith BR, Murray DM, Knight WB, Mullin RJ, Gilmer TM. *Mol. Cancer Ther.* 2001; 1:85–94. [PubMed: 12467226]
14. Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, Owens G, Alligood KJ, Spector NL. *Oncogene.* 2002; 21:6255–6263. [PubMed: 12214266]
15. Johnston SR, Leary A. *Drugs Today.* 2006; 42:441–453. [PubMed: 16894399]
16. Moy B, Kirkpatrick P, Kar S, Goss P. *Nat. Rev. Drug. Discov.* 2007; 6:431–432. [PubMed: 17633789]
17. Behera R, Thomas SM, Mensa-Wilmot K. *Antimicrob. Agents Chemother.* 2014; 58:2202–2210. [PubMed: 24468788]
18. Waterson AG, Petrov KG, Hornberger KR, Hubbard RD, Sammond DM, Smith SC, Dickson HD, Caferro TR, Hinkle KW, Stevens KL, Dickerson SH, Rusnak DW, Spehar GM, Wood ER, Griffin RJ, Uehling DE. *Bioorg. Med. Chem. Lett.* 2009; 19:1332–1336. [PubMed: 19208477]
19. Stevens KL, Alligood KJ, Alberti JG, Caferro TR, Chamberlain SD, Dickerson SH, Dickson HD, Emerson HK, Griffin RJ, Hubbard RD, Keith BR, Mullin RJ, Petrov KG, Gerding RM, Reno MJ, Rheault TR, Rusnak DW, Sammond DM, Smith SC, Uehling DE, Waterson AG, Wood ER. *Bioorg. Med. Chem. Lett.* 2009; 19:21–26. [PubMed: 19028424]
20. Hubbard RD, Dickerson SH, Emerson HK, Griffin RJ, Reno MJ, Hornberger KR, Rusnak DW, Wood ER, Uehling DE, Waterson AG. *Bioorg. Med. Chem. Lett.* 2008; 18:5738–5740. [PubMed: 18842405]
21. Wood ER, Shewchuk LM, Ellis B, Brignola P, Brashear RL, Caferro TR, Dickerson SH, Dickson HD, Donaldson KH, Gaul M, Griffin RJ, Hassell AM, Keith B, Mullin R, Petrov KG, Reno MJ, Rusnak DW, Tadepalli SM, Ulrich JC, Wagner CD, Vanderwall DE, Waterson AG, Williams JD, White WL, Uehling DE. *Proc. Nat. Acad. Sci.* 2008; 105:2773–2778. [PubMed: 18287036]
22. Caferro TR, Chamberlain SD, Donaldson KH, Harris PA, Gaul MD, Uehling DE, Vanderwall DE. 2003 WO2003053446A1.
23. Benish MA, Budde RJA, Lawless M. 2002 WO2002057271A2.
24. Buchmann B, Braeuer N, Koppitz M, Peters O, Ter LA, Lindenthal B, Langer G, Wintermantel T. WO2009007421A1. 2009
25. Huang Y, Wolf S, Bista M, Meireles L, Camacho C, Holak TA, Dömling A. *Chem. Biol. Drug Des.* 2010; 76:116–129. [PubMed: 20492448]
26. De Muylder G, Ang KK, Chen S, Arkin MR, Engel JC, McKerrow JH. *PLoS Negl. Trop. Dis.* 2011; 5:e1253. [PubMed: 21811648]

Figure 1.
Project strategy.

Scheme 1.
Synthesis of the thieno[3,2-*d*]pyrimidine template.

Scheme 2.
Synthesis of the thieno[2,3-*d*]pyrimidine Template

Figure 2.

Plot of anti-trypanosome activity as a function of R-group (X-axis) and scaffold (black-quinazoline, red = thieno[2,3-*d*]pyrimidine; green = thieno[3,2-*d*]pyrimidine. R group letter corresponds to compound substitutions listed in **Table 1**.

Table 1

Antiparasitic activities of compounds against *T. brucei*, *T. cruzi*, *L. major*, and *P. falciparum*.

Cmpd	Scaffold ^a	R	<i>T. brucei</i> EC ₅₀ (μM) or % inh (at 5 μM) ^b	<i>T. cruzi</i> EC ₅₀ (μM) or % inh (at 10 μM) ^b	<i>L. major</i>		<i>P. falciparum</i> D6 EC ₅₀ (μM) ^d
					Amast EC ₅₀ (μM) ^c	Promast EC ₅₀ (μM) ^c	
2 ^e			0.042 ± 0.010	1.8 ± 0.9	7.98 r ² = 0.75	2.97 r ² = 0.76	0.23 r ² = 0.99
11a			42%	>50	5.4 r ² = 0.81	>20	0.86 r ² = 0.98
18a			0.40 ± 0.05	2.2 ± 0.4	2.60 r ² = 0.94	>20	0.52 r ² = 0.99
4b ^e			3.9 ± 0.3	1.8 ± 0.1	>15	4.05 r ² = 0.85	0.79 r ² = 0.90
11b			2.8 ± 0.1	0%	>15	8.14 r ² = 0.86	2.97 r ² = 0.98
18b ^f			1.7 ± 0.2	42%	>15	>20	>20

Cmpd	Scaffold ^a	R	<i>T. brucei</i> EC ₅₀ (μM) or % inh (at 5 μM) ^b	<i>T. cruzi</i> EC ₅₀ (μM) or % inh (at 10 μM) ^b	<i>L. major</i>		<i>P. falciparum</i> D6 EC ₅₀ (μM) ^d
					Amast EC ₅₀ (μM) ^c	Promast EC ₅₀ (μM) ^c	
4c ^e			4.7 ± 0.2	6.4 ± 4.0	nd ^g	nd ^g	n ^g
11c			1.2 ± 0.1	0.67 ± 0.06	2.37 r ² = 0.92	>20	1.07 r ² = 0.96
18c			0.5 ± 0.2	>50.0	>15	>20	>15
4d ^e			3.2 ± 0.1	5.0 ± 0.0	4.67 r ² = 0.91	3.49 r ² = 0.82	0.52 r ² = 0.98
11d			1.4 ± 0.0	2.7 ± 2.3	>3	>3	0.65 r ² = 0.96
18d			1.3 ± 0.1	2.4 ± 1.0	>15	11.75 r ² = 0.90	0.52 r ² = 0.97
4e			1.0 ± 0.1	49%	1.14 r ² = 0.85	>20	0.26 r ² = 0.96
11e			0.084 ± 0.0	3.3 ± 1.2	>3	>3	0.23 r ² = 0.98

Cmpd	Scaffold ^a	R	<i>T. brucei</i> EC ₅₀ (μM) or % inh (at 5 μM) ^b	<i>T. cruzi</i> EC ₅₀ (μM) or % inh (at 10 μM) ^b	<i>L. major</i>		<i>P. falciparum</i> D6 EC ₅₀ (μM) ^d
					Amast EC ₅₀ (μM) ^c	Promast EC ₅₀ (μM) ^c	
18e			0.42 ± 0.1	29%	>3	>3	0.28 r ² = 0.99
4f			0.22 ± 0.00	2.2 ± 0.4	4.09 r ² = 0.92	>20	0.60 r ² = 0.96
11f			0.89 ± 0.10	30 ± 13	>15	>20	1.65 r ² = 0.98
18f			1.6 ± 0.0	17%	2.03 r ² = 0.84	>20	7.79 r ² = 0.93
4g ^e			5.3 ± 0.2	Nd	>15	6.86 r ² = 0.78	5.79 r ² = 0.98
11g			10%	>50.0	3.50 r ² = 0.84	>20	6.21 r ² = 0.46
18g			1.2 ± 0.3	45%	>15	>20	10.78 r ² = 0.94
4h ^e			0.14 ± 0.1	>50.0	>15	>3	0.51 r ² = 0.98

Cmpd	Scaffold ^a	R	<i>T. brucei</i> EC ₅₀ (μM) or % inh (at 5 μM) ^b	<i>T. cruzi</i> EC ₅₀ (μM) or % inh (at 10 μM) ^b	<i>L. major</i>		<i>P. falciparum</i> D6 EC ₅₀ (μM) ^d
					Amast EC ₅₀ (μM) ^c	Promast EC ₅₀ (μM) ^c	
11h			46%	3.2 ± 0.5	3.10 r ² = 0.93	>20	1.17 r ² = 0.94
18h			0.33 ± 0.03	>50.0	>15	>20	2.11 r ² = 0.98
4i ^e			6.0 ± 0.2	>50.0	>15	>20	0.91 r ² = 0.99
11i			8%	>50.0	>15	>20	>15
18i			2.9 ± 0.3	49%	>3	>3	>4
4j ^{ef}			1.0 ± 0.05	0.60 ± 0.15	5.91 r ² = 0.94	2.74 r ² = 0.88	0.063 r ² = 0.99
11j			1.1 ± 0.0	>50.0	>15.0	0.22 r ² = 0.84	0.027 r ² = 0.97
18j			60%	1.7 ± 0.1	4.20 r ² = 0.91	>20	0.089 r ² = 0.81

Cmpd	Scaffold ^a	R	<i>T. brucei</i> EC ₅₀ (μM) or % inh (at 5 μM) ^b	<i>T. cruzi</i> EC ₅₀ (μM) or % inh (at 10 μM) ^b	<i>L. major</i>		<i>P. falciparum</i> D6 EC ₅₀ (μM) ^d
					Amast EC ₅₀ (μM) ^c	Promast EC ₅₀ (μM) ^c	
4k ^{ef}			1.9 ± 0.9	10.1%	>15	4.40 r ² = 0.82	0.27 r ² = 0.98
11k			0.47 ± 0.25	0%	>15	>20	3.10 r ² = 0.98
4l ^e			6.5 ± 1.0	>50.0	>15	>20	>20
11l			2.2 ± 0.1	0.75 ± 0.02	1.58 r ² = 0.83	>20	0.44 r ² = 0.98
4m		H	1.3 ± 0.1	2.4 ± 0.2	12.36 r ² = 0.78	1.75 r ² = 0.77	5.33 r ² = 0.69
11m			1%	27 ± 3.5	>15	5.68 r ² = 0.94	16.4 r ² = 0.93

^a Ar is defined as 3-chloro-4-((3-fluorobenzyl)oxy)phenyl.

^b Compounds showing ±75% growth inhibition at 5 or 10 μM for *T. brucei* or *T. cruzi*, respectively, were tested for EC₅₀ values. *T. brucei* EC₅₀ values are the result of duplicate experiments, within ± 25%, with the exception of **11e** (± 33%), and **11k** (± 52%). *T. cruzi* EC₅₀ values are the result of duplicate experiments, within ± 50%, with the exception of **4c** (± 63%), and **11d** (± 85%).

^c Compounds screened against *L. major* amastigotes and promastigotes were tested in duplicate and had r² values >0.75.

^d Compounds were tested in duplicate against *P. falciparum* (D6 strain) and had r² values >0.90 except for **11g** (r² = 0.46) and **18j** (r² = 0.81) against *P. falciparum*.

^e Previously reported data utilizing the same assay as described in the Electronic Supplementary Information.⁷

^f All compounds were inactive against HepG2 cell lines except for **4b** (TC₅₀ = 4.9 μM), **4j** (12.9 μM), **4k** (9.6 μM), and **18b** (10.0 μM).

^gNot determined due to low solubility in the assay conditions.